View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Paycom Software Inc: 1 director

A director at Paycom Software Inc sold 30,000 shares at 265.228USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoir...

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit’s pipeline while preserving full ownership of intellectual property and data, maxi...

 PRESS RELEASE

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s application to transf...

 PRESS RELEASE

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance Conduit regains compliance with Bid Price and Equity RequirementsCDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with...

 PRESS RELEASE

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on May 5, 2025. They granted the b...

 PRESS RELEASE

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead ...

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Offic...

 PRESS RELEASE

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904...

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces the filing of a new composi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Southwest Airlines Co: 1 director

A director at Southwest Airlines Co bought 3,670 shares at 27.294USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 26, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 19, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

OXY OCCIDENTAL PETROLEUM CORPORATION
RGP RESOURCES CONNECTION INC.
RDNT RADNET INC.
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
NEOG NEOGEN CORPORATION
MOD MODINE MANUFACTURING COMPANY
LGND LIGAND PHARMACEUTICALS INCORPORATED
CVGW CALAVO GROWERS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
APA.. APA CORP.
LPG DORIAN LPG
WHF WHITEFIELD
AB ALLIANCEBERNSTEIN HOLDING L.P.
ADC AGREE REALTY CORPORATION
AMTX AEMETIS
CNFR CONIFER HOLDINGS
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
NHF NEXPOINT CREDIT STRATEGIES FUN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
WGO WINNEBAGO INDUSTRIES INC.
FF FIRST MINING GOLD
SONO SONOS
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
LPI LAREDO PETROLEUM INC.
KROS KEROS THERAPEUTICS
ASAN ASANA
PCVX VAXCYTE
NUVB NUVATION BIO INC (A)
UAN CVR PARTNERS LP
SMMT SUMMIT THERAPEUTICS INC
FTCI FTC SOLAR
PFBX INC.
UPST PEOPLES FINANCIAL CORP. (MISSISSIPPI)
HUMA UPSTART HOLDINGS
BFZ HUMACYTE INC
PEPG BLACKROCK CALIF MUN INCOME TRUST
EWTX PEPGEN INC
GLSI EDGEWISE THERAPEUTICS INC
JMSB GREENWICH LIFESCIENCES INC
MEGI JOHN MARSHALL BANCORP INC
NMTC MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
VANI NEUROONE MEDICAL TECHNOLOGIES CORP
PROK VIVANI MEDICAL INC
GTE PROKIDNEY CORP.
SBGI GRAN TIERRA ENERGY INC.
MIO SINCLAIR INC
NUTX PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
BATRK NUTEX HEALTH INC
ECF LIBERTY MEDIA CORPORATION
NBY ELLSWORTH FUND LTD
NOVABAY PHARMACEUTICALS INC.
 PRESS RELEASE

Conduit Pharmaceuticals Announces Leadership Changes

Conduit Pharmaceuticals Announces Leadership Changes NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VT...

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuti...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch